Clinical Pharmacology & Therapeutics
September 30, 2024
Andreas Halman, Rachel Conyers, Claire Moore et al.
13 citations
Genetic variations in drug-metabolizing enzymes, particularly cytochrome P450, can influence the intensity of acute effects from psychedelics like LSD and ibogaine, suggesting that dose reductions may be appropriate for CYP2D6 poor metabolizers. Preclinical evidence also indicates that CYP2D6 metabolizer status might alter psychedelic experiences with 5-MeO-DMT and psilocybin when combined with monoamine oxidase inhibitors. Although evidence is limited, especially for pharmacodynamics, pharmacogenomic testing warrants further investigation to potentially improve safety and personalize psychedelic-assisted therapies for psychiatric conditions.
Journal of psychoactive drugs
January 1, 2024
Reid Robison, Madeline Brendle, Claire Moore et al.
Ten frontline healthcare workers with burnout and PTSD symptoms were treated with group ketamine-assisted psychotherapy (KAP) in a private clinic. They attended six weekly sessions: one preparation, three ketamine sessions (two sublingual, one intramuscular), and two integration sessions. PTSD, depression, and anxiety scores improved from pre- to post-treatment, with a 59% reduction in PTSD scores, 58% reduction in depression scores, and 36% reduction in anxiety scores. After treatment, all participants screened negative for PTSD, 90% had minimal or mild depression, and 60% had minimal or mild anxiety. Ketamine was well tolerated with no significant adverse events. Participant feedback supported the improvements.
Journal of eating disorders
May 6, 2022
Reid Robison, Adele Lafrance, Madeline Brendle et al.
In a small case series of five patients with eating disorders and co-occurring mood and anxiety disorders, group-based ketamine-assisted psychotherapy (G-KAP) delivered weekly over four weeks in a residential treatment setting was associated with clinically significant improvements in depression scores (PHQ-9) for four of five participants and in anxiety scores (GAD-7) for two of five participants, measured from before dosing to 24 hours after the final session. No serious adverse events occurred, and the protocol was reported as practical to implement. The findings suggest G-KAP may be a useful adjunct to intensive eating disorder treatment, though further research is needed.
Brain sciences
March 12, 2022
Anya Ragnhildstveit, Matthew Slayton, Laura Kate Jackson et al.
Eating disorders are serious psychiatric conditions with limited treatment options. Ketamine, a drug approved for treatment-resistant depression, is now being investigated for eating disorders. This review examines the evidence for ketamine in treating anorexia nervosa, bulimia nervosa, and binge eating disorder. Results are encouraging but limited to case reports on anorexia nervosa. More research is needed to determine ketamine's effectiveness across different eating disorder types, establish safety, and optimize dosing.